マクロファージ遊走阻止因子治療薬市場:パイプラインレビュー(2019年下半期)

【英語タイトル】Macrophage Migration Inhibitory Factor - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA20MY0338)・商品コード:GDATA20MY0338
・発行会社(調査会社):Global Markets Direct
・発行日:2019年12月27日
・ページ数:50
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥364,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥728,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,092,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Macrophage Migration Inhibitory Factor – Pipeline Review, H2 2019
Summary

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Macrophage Migration Inhibitory Factor – Pipeline Review, H2 2019, outlays comprehensive information on the Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) – Macrophage migration inhibitory factor (MIF) also known as glycosylation-inhibiting factor (GIF) is a protein that is encoded by the MIF gene. Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine produced by the pituitary gland and multiple cell types, including macrophages, dendritic cells (DC) and T-cells. Upon releases MIF modulates the expression of several inflammatory molecules, such as TNF-α, nitric oxide and cyclooxygenase 2 (COX-2). MIF is an important regulator of innate immunity. Antigens stimulate white blood cells to release MIF into the blood stream. The circulating MIF binds to CD74 on other immune cells and trigger an acute immune response. MIF plays a role in the regulation of macrophage function in host defense through the suppression of anti-inflammatory effects of glucocorticoid. The molecules developed by companies in Preclinical and Discovery stages are 8 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders, Respiratory, Dermatology and Infectious Disease which include indications Rheumatoid Arthritis, Glomerulonephritis, Inflammatory Bowel Disease, Multiple Sclerosis, Pulmonary Arterial Hypertension, Type 1 Diabetes (Juvenile Diabetes), Alzheimer’s Disease, Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Crohn’s Disease (Regional Enteritis), Idiopathic Pulmonary Fibrosis, Inflammation, Malaria, Myocardial Infarction, Obesity, Prostate Cancer, Psoriasis, Systemic Lupus Erythematosus, Type 2 Diabetes and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12)
- The report reviews Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics and enlists all their major and minor projects
- The report assesses Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) – Overview
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) – Companies Involved in Therapeutics Development
Apaxen
GlaxoSmithKline Plc
Ibex Biosciences LLC
Innovimmune Biotherapeutics Inc
L2 Diagnostics LLC
Mifcare
MIFCOR Inc
Takeda Pharmaceutical Co Ltd
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) – Drug Profiles
BaxB-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BaxG-03 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-88 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
malaria vaccine 1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MFC-1040 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MFC-2040 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIF-20 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibits MIF for Prostate Cancer – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-425 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MIF for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Macrophage Migration Inhibitory Factor for Type 1 Diabetes – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MIF for Autoimmune Disorders and Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MIF for Inflammatory Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MIF for Multiple Sclerosis and Rheumatoid Arthritis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) – Dormant Products
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) – Discontinued Products
Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) – Product Development Milestones
Featured News & Press Releases
Jul 13, 2018: Yale researchers identify target for novel malaria vaccine
Jan 10, 2017: Abzyme receives Milestone Payment from Ibex for Anti-cancer VHH Antibodies
Sep 09, 2016: Mifcare Announces Positive Preclinical Efficacy Data for MFC1040 in Sugen/Chronic Hypoxia Model of Severe Pulmonary Arterial Hypertension
Jul 15, 2016: Mifcare Announces Positive Preclinical Results with MFC1040 in Pulmonary Arterial Hypertension
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Apaxen, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Ibex Biosciences LLC, H2 2019
Pipeline by Innovimmune Biotherapeutics Inc, H2 2019
Pipeline by L2 Diagnostics LLC, H2 2019
Pipeline by Mifcare, H2 2019
Pipeline by MIFCOR Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Apaxen
GlaxoSmithKline Plc
Ibex Biosciences LLC
Innovimmune Biotherapeutics Inc
L2 Diagnostics LLC
Mifcare
MIFCOR Inc
Takeda Pharmaceutical Co Ltd

★調査レポート[マクロファージ遊走阻止因子治療薬市場:パイプラインレビュー(2019年下半期)] (コード:GDATA20MY0338)販売に関する免責事項を必ずご確認ください。
★調査レポート[マクロファージ遊走阻止因子治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆